Efficacy and safety of finerenone in patients with chronic kidney disease and type 2 diabetes by GLP-1RA treatment: A subgroup analysis from the FIDELIO-DKD trial

Further Publications Urology

Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial

Lancet Diabetes Endocrinol

Heerspink HJL, Jongs N, Chertow GM, Langkilde AM, McMurray JJV, Correa-Rotter R, Rossing P, Sjöström CD, Stefansson BV, Toto RD, Wheeler DC, Greene T, DAPA-CKD Trial Committees and Investigators.

doi: 10.1016/S2213-8587(21)00242-4

Lower Urinary Tract SymptomsFurther Publications Urology

Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial

Lancet Diabetes Endocrinol

Jongs N, Greene T, Chertow GM, McMurray JJV, Langkilde AM, Correa-Rotter R, Rossing P, Sjöström CD, Stefansson BV, Toto RD, Wheeler DC, Heerspink HJL, DAPA-CKD Trial Committees and Investigators.

doi: 10.1016/S2213-8587(21)00243-6

Urinary Incontinence

Spectrum and dosing of urate-lowering drugs in a large cohort of chronic kidney disease patients and their effect on serum urate levels: a cross-sectional analysis from the German Chronic Kidney Disease study

Clin Kidney J

Kielstein JT, Heisterkamp M, Jing J, Nadal J, Schmid M, Kronenberg F, Busch M, Sommerer C, Lorenzen JM, Eckardt KU, Köttgen A, GCKD Study Investigators.

doi: 10.1093/ckj/sfz136

Coronary Artery Calcification and Risk of Cardiovascular Disease and Death Among Patients With Chronic Kidney Disease

JAMA Cardiol.

Chen J, Budoff MJ, Reilly MP, Yang W, Rosas SE, Rahman M, Zhang X, Roy JA, Lustigova E, Nessel L, Ford V, Raj D, Porter AC, Soliman EZ, Wright JT Jr, Wolf M, He J

doi: 10.1001/jamacardio.2017.

Rapid Occurrence of Chronic Kidney Disease in Patients Experiencing Reversible Acute Kidney Injury after Cardiac Surgery

Anesthesiology.

Legouis D, Galichon P, Bataille A, Chevret S, Provenchère S, Boutten A, Buklas D, Fellahi JL, Hanouz JL, Hertig A

doi: 10.1097/ALN.

Uro-Oncology

Efficacy and Safety of Atezolizumab Plus Bevacizumab Following Disease Progression on Atezolizumab or Sunitinib Monotherapy in Patients with Metastatic Renal Cell Carcinoma in IMmotion150: A Randomized Phase 2 Clinical Trial

Eur Urol

Powles T, Atkins MB, Escudier B, Motzer RJ, Rini BI, Fong L, Joseph RW, Pal SK, Sznol M, Hainsworth J, Stadler WM, Hutson TE, Ravaud A, Bracarda S, Suarez C, Choueiri TK, Reeves J, Cohn A, Ding B, Leng N, Hashimoto K, Huseni M, Schiff C, McDermott DF

doi: 10.1016/j.eururo.2021.01.003

Overactive Bladder

Safety and Efficacy of Mirabegron: Analysis of a Large Integrated Clinical Trial Database of Patients with Overactive Bladder Receiving Mirabegron, Antimuscarinics, or Placebo

Eur Urol.

Chapple CR, Cruz F, Cardozo L, Staskin D, Herschorn S, Choudhury N, Stoelzel M, Heesakkers J, Siddiqui E

doi: 10.1016/j.eururo.2019.09.024.

Further Publications Urology

Impact of kidney function on the safety and efficacy of insulin degludec versus insulin glargine U300 in people with type 2 diabetes: A post hoc analysis of the CONCLUDE trial

Diabetes Obes Metab

Pieber TR, Bajaj HS, Heller SR, Jia T, Khunti K, Klonoff DC, Ladelund S, Leiter LA, Wagner L, Philis-Tsimikas A

doi: 10.1111/dom.14564

Hypogonadism

Clinical and biochemical correlates of male hypogonadism in type 2 diabetes

Andrology.

Herrero A, Marcos M, Galindo P, Miralles JM, Corrales JJ

doi: 10.1111/andr.12433.

Related content